{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/palliative-care-dyspnoea/prescribing-information/oxygen/","result":{"pageContext":{"chapter":{"id":"22221f0a-e6f8-5976-bf6c-1024268816e0","slug":"oxygen","fullItemName":"Oxygen","depth":2,"htmlHeader":"<!-- begin field d1be6d07-f674-4db0-8eda-79c0de85cab8 --><h2>Oxygen</h2><!-- end field d1be6d07-f674-4db0-8eda-79c0de85cab8 -->","summary":"","htmlStringContent":"<!-- begin item e457258f-8485-4dbb-aa0d-c1c28697015a --><!-- end item e457258f-8485-4dbb-aa0d-c1c28697015a -->","topic":{"id":"20d4363b-caf3-55a9-beed-09266efa45f4","topicId":"73af552e-909d-456c-86d1-11f7a65040d8","topicName":"Palliative care - dyspnoea","slug":"palliative-care-dyspnoea","lastRevised":"Last revised in November 2020","chapters":[{"id":"0614f3a6-7238-5427-b059-9195b0cc2aa1","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"738e7584-0909-59c3-bd54-43100aed01fe","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"ea721a0d-cda2-5620-8e3f-61e76920b9b3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"83260a2e-73f3-5abd-b049-c307d85d2cff","slug":"changes","fullItemName":"Changes"},{"id":"460710fb-be39-5a74-8adf-44beac90510f","slug":"update","fullItemName":"Update"}]},{"id":"a2422ca0-3b24-5c6e-81d8-07d257fdd44a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2753bf62-a22c-5fb2-936c-554ef07426d4","slug":"goals","fullItemName":"Goals"},{"id":"65f25469-16d4-5c7f-b7bc-a6698ca61164","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"52a827c5-48de-5c0c-8dce-6c7eeeab720d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"cd3e39be-06ce-5750-a1f7-cbc06bb58756","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"50c51a08-6607-5699-96a8-d66cb532d2c5","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"05dc5599-43b4-5340-841b-3b3208f4b947","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"1fd04fd1-0023-5c48-9785-d9a54c7e2eb0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5a84982b-be4e-5901-a577-110f09001119","slug":"definition","fullItemName":"Definition"},{"id":"dab82422-38f4-5a30-b0db-ad2cbf33c2ab","slug":"prevalence-of-dyspnoea-in-palliative-care","fullItemName":"Prevalence of dyspnoea in palliative care"},{"id":"ea086054-ae8f-5666-9159-99b04676d230","slug":"causes-of-dyspnoea","fullItemName":"Causes of dyspnoea"},{"id":"c2601cd4-69b1-563f-870a-8110f4c24103","slug":"complications-of-dyspnoea","fullItemName":"Complications of dyspnoea"}]},{"id":"db288340-b73c-59b1-a8ba-4baec577b887","fullItemName":"Management","slug":"management","subChapters":[{"id":"62ed0387-08f9-5656-8079-a5fffee537f4","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"cdb4ccb3-9b96-5651-9950-6e2e0b8f4da0","slug":"symptomatic-treatment","fullItemName":"Scenario: Symptomatic treatment"},{"id":"5b9d65e3-1fc3-558d-a95e-5e4ff147c7d7","slug":"known-cause-of-dyspnoea","fullItemName":"Scenario: Known cause of dyspnoea"},{"id":"3b6b57e5-ba14-5311-bbf3-d996401c7dc6","slug":"end-of-life-care","fullItemName":"Scenario: End of life care"},{"id":"9983f052-047c-5346-adfc-b741909ce269","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"08f118cb-d39f-532d-b39f-fa97739c656d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"22221f0a-e6f8-5976-bf6c-1024268816e0","slug":"oxygen","fullItemName":"Oxygen"},{"id":"25b01dc5-45e8-563d-872f-cfec63e33029","slug":"opioids","fullItemName":"Opioids"},{"id":"b7f561a2-0802-545a-b7d1-db218387a6e5","slug":"benzodiazepines","fullItemName":"Benzodiazepines"}]},{"id":"9f0bdd3b-82e3-5cbb-908f-d36a887457a8","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5c3c7cfe-04b9-5ac4-9255-be56a20c7b5c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"3aa322d7-2279-512c-93a7-55426d21da21","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b889ecee-814d-5e79-b596-a024fbee0acf","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7e27fb69-52fd-5ddc-8f84-6164bb8615d0","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c1800f44-6de2-534a-a4ff-32b8b5cf6e24","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6b7633c0-45a5-5a2e-b564-f185c2b9ef5f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2d28faa0-4a5f-565b-a431-6339d01f6e91","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"08f118cb-d39f-532d-b39f-fa97739c656d","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"6a64d8da-b019-5f15-a21f-6d0a5ae040c5","slug":"how-to-order","fullItemName":"How to order","depth":3,"htmlHeader":"<!-- begin field 8140eb92-0a6e-4bf6-8855-53a24934b1b1 --><h3>How should I order home oxygen?</h3><!-- end field 8140eb92-0a6e-4bf6-8855-53a24934b1b1 -->","summary":"","htmlStringContent":"<!-- begin item 6873cc21-9fd0-407d-b1dc-d753e18ca5d7 --><!-- begin field e0e6641a-af57-4f8f-aa67-a897e76c4887 --><ul><li><strong>On 1 February 2006 the supply of home oxygen </strong>was transferred from community pharmacies to regional oxygen supply companies in England and Wales. These companies are responsible for supplying cylinders, concentrators, and liquid oxygen as part of an integrated service.</li><li><strong>Oxygen is ordered from one of four regional supply companies </strong>using the Home Oxygen Order Form (HOOF), which has replaced prescribing of oxygen on FP10 prescriptions.</li><li>Key documentation for Home Oxygen Services (including <a href=\"http://www.bprs.co.uk/documents/oxygen/HOOF.pdf\" data-hyperlink-id=\"a56ab145-ff00-4c25-9705-a99200a3fb44\">HOOF</a>s) is available from your local Primary Care Trust or online at <a href=\"http://www.pcc.nhs.uk/\" data-hyperlink-id=\"e65f6493-e7ca-4d92-902f-a99200a3fb5a\">www.pcc.nhs.uk</a> </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">BNF 72, 2016</a>]</p><!-- end field e0e6641a-af57-4f8f-aa67-a897e76c4887 --><!-- end item 6873cc21-9fd0-407d-b1dc-d753e18ca5d7 -->","subChapters":[]},{"id":"f49c1aa1-1b55-594a-bcc4-9c1d3c9fecdf","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field b71c4eb8-d994-4dc5-809a-9187d26b914c --><h3>What are the adverse effects of home oxygen therapy?</h3><!-- end field b71c4eb8-d994-4dc5-809a-9187d26b914c -->","summary":"","htmlStringContent":"<!-- begin item 836c534e-7a4e-4faa-93e0-cf4e9e60f247 --><!-- begin field 6f9b3bb5-f754-4738-9abb-1a55b36b38ca --><ul><li>Oxygen therapy has potential psychosocial and drug-induced adverse effects which can influence patient acceptability and tolerability, and hence compliance.</li><li>Psychosocial adverse effects include:<ul><li>Psychological dependence. Being deprived of oxygen for even a short period may provoke acute anxiety and hence dyspnoea.</li><li>Social restriction. Oxygen equipment severely limits mobility inside and outside the house, and some people feel a social stigma and embarrassment.</li></ul></li><li>Drug-induced adverse effects include:<ul><li>Oxygen toxicity. High concentrations over long periods can cause lung damage.</li><li>Lung atelectasis. Oxygen is very soluble and may cause a reduced amount of air in part of the lungs, resulting in a loss of lung volume.</li><li>Drying of airways. Oxygen therapy contains less water vapour than air, which can lead to discomfort owing to its drying effect, particularly on the nasal mucosa when using nasal cannulae.</li><li>Combustibility. People receiving oxygen therapy must not smoke or use oxygen while close to gas stoves or lighted fireplaces because of the fire hazard.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">Booth and Dudgeon, 2006</a>]</p><!-- end field 6f9b3bb5-f754-4738-9abb-1a55b36b38ca --><!-- end item 836c534e-7a4e-4faa-93e0-cf4e9e60f247 -->","subChapters":[]},{"id":"a252aa49-cc11-508d-a0eb-ab9377b9f7b0","slug":"practical-prescribing-issues","fullItemName":"Practical prescribing issues","depth":3,"htmlHeader":"<!-- begin field 4ad841ed-fcc9-41a2-b145-b07108c708d9 --><h3>Practical prescribing issues of oxygen therapy</h3><!-- end field 4ad841ed-fcc9-41a2-b145-b07108c708d9 -->","summary":"","htmlStringContent":"<!-- begin item a2863151-bc5c-4a05-bbaf-3c291b4477b3 --><!-- begin field 5c3af3ca-96ad-4526-8fd9-c10bb33eb723 --><ul><li>Once a decision has been made to prescribe oxygen, consider the need for oxygen concentrators, oxygen cylinders, and liquid oxygen. The choice is determined primarily by the person's lifestyle and mobility and the need for either short-burst oxygen therapy or long-term therapy.</li><li>A mask or nasal cannulae (consisting of two prongs) are options for oxygen delivery. Nasal cannulae may be preferred to a mask because they do not impair speech or eating and drinking. However, nasal cannulae can cause dryness and soreness of the nasal mucosa [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">Twycross, 2014</a>].</li><li>Oxygen should be prescribed at the lowest flow rate possible to produce benefit because of potential adverse effects:<ul><li>Clinical assessment may involve measuring breathlessness scores at different flow rates of oxygen. Most people require a flow rate of 2–4 L/min.</li></ul></li><li>People starting oxygen therapy should be provided with education and written instructions which include advice about the dangers of smoking near oxygen therapy.</li><li>People should be reassessed regularly after commencing therapy, to determine the continuing efficacy of supplemental oxygen over the longer term.</li></ul><!-- end field 5c3af3ca-96ad-4526-8fd9-c10bb33eb723 --><!-- end item a2863151-bc5c-4a05-bbaf-3c291b4477b3 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}